MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.
News
Opioid analgesics, Z-drugs linked to harmful effects in dementia patients
Medicines commonly prescribed to dementia patients have been linked to an increase in harmful side-effects, according to new research involving the University of Exeter and King’s College London.
ViiV unveils positive data for two-drug HIV regimens
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
US approves AbbVie/Neurocrine’s uterine pain drug
AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
HPV jab will be given to boys in England, gov’t confirms
The government has confirmed that boys in England will be vaccinated against the human papilloma virus in line with recent recommendations from the Joint Committee on Vaccination and Immunisation (JCVI).
JCVI backs HPV jab for boys
Government advisors are recommending that the national HPV immunisation programme in England should include boys as well as girls.
Lilly to progress Olumiant into PhIII for lupus
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
Lilly links with Anima
Eli Lilly is teaming up with Anima Biotech in an exclusive collaboration to discover and develop translation inhibitors for several protein targets.
AstraZeneca sells Atacand rights to Cheplapharm
AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
FDA staff question efficacy of GSK’s Nucala for COPD
US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD).
GSK considers splitting up
GlaxoSmithKline is reportedly considering whether to split its business into a consumer health spin-off and standalone pharmaceutical and vaccines group.
‘Workforce, technology and prevention’ NHS priorities, says Hancock
MP Matt Hancock has unveiled what he sees as “early priorities” in his new role as health and social care secretary: workforce, technology, and prevention.
US approves first-in-class targeted AML therapy
US regulators have approved the first targeted therapy for patients with relapsed or refractory acute myeloid leukemia carrying a certain genetic mutation.
Pfizer bags approval for Neupogen biosimilar
Pfizer’s Neupogen biosimilar Nivestym has been approved by the US Food and Drug Administration and is expected to hit the market at a “significant discount” to its reference drug.
PureTech lifted by news of Roche deal
Shares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion.
